DCP
AEGR

DSM Capital Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

DSM Capital Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-42,620
Closed -$1.42M – 69
2014
Q3 		$1.42M Buy
42,620
+5,855
+16% +$182K 0.03% 48
2014
Q2 		$1.18M Buy
36,765
+4,635
+14% +$173K 0.02% 54
2014
Q1 		$1.48M Buy
32,130
+9,035
+39% +$530K 0.03% 44
2013
Q4 		$1.64M Buy
23,095
+6,070
+36% +$464K 0.03% 39
2013
Q3 		$1.46M Buy
17,025
+5,490
+48% +$465K 0.03% 42
2013
Q2 		$731K Buy
+11,535
New +$612K 0.02% 66

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DSM Capital Partners's AEGR Position: Q4 2014 in Review

DSM Capital Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 42,620 shares — an estimated $1.42M sold.

DSM Capital Partners first reported a position in AEGR in Q2 2013 and held it in 6 quarters. The position peaked at $1.64M in Q4 2013. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • DSM Capital Partners reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • DSM Capital Partners sold 42,620 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $1.42M.
  • DSM Capital Partners first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • DSM Capital Partners's Aegerion Pharmaceuticals position peaked at $1.64M in Q4 2013.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on DSM Capital Partners's 13F filing for Q4 2014, filed 12 Feb 2015.